Genetic association between cyclin D1 polymorphism and breast cancer susceptibility. 2014

XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, drlixaorui@126.com.

Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. This study was undertaken to derive a precise risk estimate for the cyclin D1 polymorphism associated with breast cancer risk. We performed a search of EMBASE, PubMed, and Web of Science. In total, data from 18 publications were pooled and the association was assessed by odds ratios (ORs) with 95 % confidence intervals (CIs). This analysis showed that there was no obvious association between the cyclin D1 polymorphism and breast cancer risk in any of the analyzed genetic model. We found the same negative association in stratified analyses by ethnicity, source of controls, and sample size. Our meta-analysis provides an estimate that the presence of cyclin D1 polymorphism may not confer susceptibility to breast cancer.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D017594 Publication Bias The influence of study results on the chances of publication and the tendency of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings. Publication bias has an impact on the interpretation of clinical trials and meta-analyses. Bias can be minimized by insistence by editors on high-quality research, thorough literature reviews, acknowledgement of conflicts of interest, modification of peer review practices, etc. Bias, Publication
D019938 Cyclin D1 Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms. CCND1 Protein,PRAD1 Protein,Proto-Oncogene Proteins c-bcl-1,bcl-1 Proto-Oncogene Proteins,c-bcl-1 Proteins,Proto-Oncogene Products bcl-1,Proto-Oncogene Protein bcl-1,bcl-1 Proto-Oncogene Products,bcl1 Proto-Oncogene Proteins,Proto Oncogene Products bcl 1,Proto Oncogene Protein bcl 1,Proto Oncogene Proteins c bcl 1,Proto-Oncogene Products, bcl-1,Proto-Oncogene Proteins, bcl-1,Proto-Oncogene Proteins, bcl1,bcl 1 Proto Oncogene Products,bcl 1 Proto Oncogene Proteins,bcl-1, Proto-Oncogene Protein,bcl1 Proto Oncogene Proteins,c bcl 1 Proteins,c-bcl-1, Proto-Oncogene Proteins

Related Publications

XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
February 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
July 2006, Head & neck,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
March 2016, Medical science monitor : international medical journal of experimental and clinical research,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
June 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
January 2009, Hepato-gastroenterology,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
January 2009, In vivo (Athens, Greece),
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
October 2016, Oncotarget,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
November 2013, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
January 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
XiaoRui Li, and XiaoQing Huo, and WeiWei Li, and QingHui Yang, and Ying Wang, and XiaoChun Kang
June 2013, Indian journal of biochemistry & biophysics,
Copied contents to your clipboard!